|
| Aurobindo expands licensing pact with Pfizer, adds 60 drugs |
| BS Reporter / Hyderabad May 21, 2009, 11:38 IST |
|
Aurobindo Pharma Limited, a Hyderabad-based manufacturer of generic pharmaceuticals and active pharmaceutical ingredients (APIs), has further expanded its partnership with global pharma major Pfizer Inc by executing licensing and supply agreements with the latter for solid dosage and sterile products for a number of emerging markets.
Under the terms of the pact, Pfizer has acquired rights to 55 solid oral dose and 5 sterile injectable products for several countries throughout Asia, Latin America and West Asia. These products fall under a broad range of some important therapeutic segments like anti-infectives, cardivascular (CVS) and central nervous system (CNS) disorders.
“The expansion of our product portfolio from this deal provides a foundation for us to commercialise branded generics based on patient needs within specific regions,” Jean-Michel Halfon, president and general manager (emerging markets business unit), Pfizer, stated in a press release on Thursday.
Aurobindo’s product portfolio is spread over six major therapeutic and product areas comprising antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals and anti-allergics. The company markets these products in over 100 countries.
|
|
|
|
|
|
|
|
|
|
 Read Business news in |  |
|
|
|
|
|
|
Advertisements |
|
|
|
|
|
|
|
|
|
|
Content Guide
